NASDAQ:VRAX Virax Biolabs Group (VRAX) Stock Price, News & Analysis $0.67 +0.04 (+6.47%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.01 (+2.14%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings About Virax Biolabs Group Stock (NASDAQ:VRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virax Biolabs Group alerts:Sign Up Key Stats Today's Range$0.60▼$0.7050-Day Range$0.63▼$2.8552-Week Range$0.50▼$21.75Volume79,802 shsAverage Volume849,916 shsMarket Capitalization$534.16 thousandP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview Virax Biolabs Group Limited (NASDAQ: VRAX) is a biotechnology company focused on the prevention, detection and diagnosis of viral diseases. The company develops and commercializes diagnostic technologies designed to help identify infections and evaluate immune responses to viral pathogens. Its product portfolio has included Virax Immune, a T-cell-based test intended to assess cellular immune responses to SARS-CoV-2 and other viral threats. Virax Biolabs has also pursued rapid testing and diagnostic solutions for infectious diseases, with offerings marketed through healthcare, laboratory and distribution channels. Founded in the United Kingdom, Virax Biolabs serves international markets and has focused on expanding access to viral testing and immune-profiling technologies. The company has been led by James Foster, who has experience in the diagnostics and healthcare sectors.AI Generated. May Contain Errors. Read More Virax Biolabs Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreVRAX MarketRank™: 3.062385561075 of 5 starsVirax Biolabs Group scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingVirax Biolabs Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialVirax Biolabs Group has a consensus price target of $25.00, representing about 3,644.2% upside from its current price of $0.67.Amount of Analyst CoverageVirax Biolabs Group has only been the subject of 1 research reports in the past 90 days.Read more about Virax Biolabs Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioVirax Biolabs Group has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Virax Biolabs Group's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.53% of the float of Virax Biolabs Group has been sold short.Short Interest Ratio / Days to CoverVirax Biolabs Group has a short interest ratio ("days to cover") of 0.28, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virax Biolabs Group has recently decreased by 25.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVirax Biolabs Group does not currently pay a dividend.Dividend GrowthVirax Biolabs Group does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentVirax Biolabs Group has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Virax Biolabs Group this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Virax Biolabs Group insiders have not sold or bought any company stock.Percentage Held by Insiders45.10% of the stock of Virax Biolabs Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.61% of the stock of Virax Biolabs Group is held by institutions.Read more about Virax Biolabs Group's insider trading history. Receive VRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRAX Stock News HeadlinesVirax Biolabs Group (NASDAQ:VRAX) Stock Price Down 9.1% - Here's What HappenedNovember 3, 2026 | americanbankingnews.comVirax Biolabs Signs Three Mainland China Distributors for ImmuneSelect Research PortfolioOctober 29, 2026 | tipranks.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 12 at 1:00 AM | Base Camp Trading (Ad)Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland ChinaOctober 29, 2026 | prnewswire.comVirax Biolabs Restructures Leadership to Prioritize ViraxImmune DevelopmentOctober 9, 2026 | tipranks.comVirax Biolabs Expands ATM Share Offering With New SEC FilingSeptember 4, 2026 | tipranks.comVirax Biolabs Shareholders Approve Major Capital Increase but Reject Governance OverhaulAugust 26, 2026 | tipranks.comJoin Virax’s Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial ExecutionAugust 20, 2026 | usatoday.comSee More Headlines VRAX Stock Analysis - Frequently Asked Questions How have VRAX shares performed this year? Virax Biolabs Group's stock was trading at $8.6450 at the beginning of 2026. Since then, VRAX shares have decreased by 92.3% and is now trading at $0.6677. How were Virax Biolabs Group's earnings last quarter? Virax Biolabs Group Limited (NASDAQ:VRAX) posted its quarterly earnings data on Friday, July, 3rd. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($1.75) by $1.56. The business earned $5.41 thousand during the quarter, compared to analyst estimates of $1 thousand. When did Virax Biolabs Group's stock split? Shares of Virax Biolabs Group reverse split before market open on Friday, June 26th 2026.The 1-25 reverse split was announced on Wednesday, June 24th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 26th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Virax Biolabs Group IPO? Virax Biolabs Group (VRAX) raised $7 million in an initial public offering (IPO) on Thursday, July 21st 2022. The company issued 1,400,000 shares at a price of $5.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Virax Biolabs Group? Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virax Biolabs Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virax Biolabs Group investors own include Cyclerion Therapeutics (KRSA), Tonix Pharmaceuticals (TNXP), Financial Select Sector SPDR Fund (XLF), American Battery Technology (ABML), Anaconda Mining (ANXGF), Angus Energy (ANGS) and Aditxt (ADTX). Company Calendar Today11/12/2026Next Earnings (Estimated)12/02/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 10 days, VRAX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:VRAX CIK1885827 Webviraxbiolabs.com Phone44-0-20-7788-7414FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Price Target for Virax Biolabs Group$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+3,644.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.97 Quick Ratio9.97 Sales & Book Value Annual Sales$10 thousand Price / Sales53.42 Cash FlowN/A Price / Cash FlowN/A Book Value$42.23 per share Price / Book0.02Miscellaneous Outstanding Shares800,000Free Float438,000Market Cap$534.16 thousand OptionableNot Optionable Beta1.50 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:VRAX) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
